| pubmed-article:8961509 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:8961509 | lifeskim:mentions | umls-concept:C0042769 | lld:lifeskim |
| pubmed-article:8961509 | lifeskim:mentions | umls-concept:C0026809 | lld:lifeskim |
| pubmed-article:8961509 | lifeskim:mentions | umls-concept:C0005149 | lld:lifeskim |
| pubmed-article:8961509 | lifeskim:mentions | umls-concept:C0026565 | lld:lifeskim |
| pubmed-article:8961509 | lifeskim:mentions | umls-concept:C0042196 | lld:lifeskim |
| pubmed-article:8961509 | lifeskim:mentions | umls-concept:C0011155 | lld:lifeskim |
| pubmed-article:8961509 | lifeskim:mentions | umls-concept:C0439662 | lld:lifeskim |
| pubmed-article:8961509 | lifeskim:mentions | umls-concept:C0127400 | lld:lifeskim |
| pubmed-article:8961509 | pubmed:issue | 13 | lld:pubmed |
| pubmed-article:8961509 | pubmed:dateCreated | 1997-3-7 | lld:pubmed |
| pubmed-article:8961509 | pubmed:abstractText | Intracranial (i.c.) infection of immunocompetent mice with lymphocytic choriomeningitis virus (LCMV) results in immunopathological lethal meningitis mediated by CD8+ cytotoxic T lymphocytes (CTL). Vaccination of immunocompetent mice elicits a CD8+ CTL response that can protect the mice from lethal meningitis. beta 2 microglobulin-deficient (beta 2m-/-) mice are deficient in CD8+ CTL, exhibit CD4+ CTL, and, after i.c. LCMV infection, undergo a less severe meningitis with decreased mortality and additionally develop a wasting disease. Both wasting disease and mortality in beta 2m-/- mice are mediated by CD4+ T cells. We studied the effects of vaccination and challenge dose on weight loss, mortality and viral clearance after i.c. LCMV infection in beta 2m-/- mice. Unvaccinated beta 2m-/- mice had significant weight loss and mortality at doses of 200 and 10(3) p.f.u. LCMV, while a dose of 10(6) p.f.u. LCMV elicited significant mortality but less weight loss. Vaccination with u.v.-inactivated LCMV in complete Freund's adjuvant or with vaccinia virus expressing the LCMV glycoprotein or nucleoprotein genes protected beta 2m-/- mice from mortality but not weight loss after 200 p.f.u. LCMV challenge. Although protected from mortality, beta 2m-/- mice were unable to clear LCMV from their brains or spleens. Therefore, we show that vaccination can protect against lethal immune-meningitis in the face of persistent infection. | lld:pubmed |
| pubmed-article:8961509 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8961509 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8961509 | pubmed:language | eng | lld:pubmed |
| pubmed-article:8961509 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8961509 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:8961509 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8961509 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8961509 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:8961509 | pubmed:month | Sep | lld:pubmed |
| pubmed-article:8961509 | pubmed:issn | 0264-410X | lld:pubmed |
| pubmed-article:8961509 | pubmed:author | pubmed-author:MullerDD | lld:pubmed |
| pubmed-article:8961509 | pubmed:author | pubmed-author:WhittonJ LJL | lld:pubmed |
| pubmed-article:8961509 | pubmed:author | pubmed-author:SalvatoMM | lld:pubmed |
| pubmed-article:8961509 | pubmed:author | pubmed-author:HildemanDD | lld:pubmed |
| pubmed-article:8961509 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:8961509 | pubmed:volume | 14 | lld:pubmed |
| pubmed-article:8961509 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:8961509 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:8961509 | pubmed:pagination | 1223-9 | lld:pubmed |
| pubmed-article:8961509 | pubmed:dateRevised | 2008-11-20 | lld:pubmed |
| pubmed-article:8961509 | pubmed:meshHeading | pubmed-meshheading:8961509-... | lld:pubmed |
| pubmed-article:8961509 | pubmed:meshHeading | pubmed-meshheading:8961509-... | lld:pubmed |
| pubmed-article:8961509 | pubmed:meshHeading | pubmed-meshheading:8961509-... | lld:pubmed |
| pubmed-article:8961509 | pubmed:meshHeading | pubmed-meshheading:8961509-... | lld:pubmed |
| pubmed-article:8961509 | pubmed:meshHeading | pubmed-meshheading:8961509-... | lld:pubmed |
| pubmed-article:8961509 | pubmed:meshHeading | pubmed-meshheading:8961509-... | lld:pubmed |
| pubmed-article:8961509 | pubmed:meshHeading | pubmed-meshheading:8961509-... | lld:pubmed |
| pubmed-article:8961509 | pubmed:meshHeading | pubmed-meshheading:8961509-... | lld:pubmed |
| pubmed-article:8961509 | pubmed:meshHeading | pubmed-meshheading:8961509-... | lld:pubmed |
| pubmed-article:8961509 | pubmed:meshHeading | pubmed-meshheading:8961509-... | lld:pubmed |
| pubmed-article:8961509 | pubmed:year | 1996 | lld:pubmed |
| pubmed-article:8961509 | pubmed:articleTitle | Vaccination protects beta 2 microglobulin deficient mice from immune mediated mortality but not from persisting viral infection. | lld:pubmed |
| pubmed-article:8961509 | pubmed:affiliation | Department of Medical Microbiology and Immunology, University of Wisconsin-Madison 53706, USA. | lld:pubmed |
| pubmed-article:8961509 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:8961509 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| pubmed-article:8961509 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8961509 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8961509 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8961509 | lld:pubmed |
